Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin.
This is the third Research Note addressing pharmacoeconomics in prescribing research, reflecting the increasing use of economic evaluation in drug purchasing decisions in a variety of settings. In this segment we provide an overview of the theoretical basis, practical application and methodological limitations of cost-effectiveness analysis (CEA).
Lopert
R
R
Pharmaceutical Benefits Branch, Department of Health and Ageing, Canberra, ACT, Australia. ruth.lopert@health.gov.au
Lang
D L
DL
Hill
S R
SR
D003362:Cost-Benefit Analysis / Q000379:methods*; D003657:Decision Making; D016527:Drug Costs / Q000706:statistics & numerical data*; D004358:Drug Therapy / Q000191:economics*; D017850:Economics, Pharmaceutical; D006138:Guaiac / Q000191:economics
D006138:Guaiac